[go: up one dir, main page]

WO2003068921A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2003068921A3
WO2003068921A3 PCT/US2003/004188 US0304188W WO03068921A3 WO 2003068921 A3 WO2003068921 A3 WO 2003068921A3 US 0304188 W US0304188 W US 0304188W WO 03068921 A3 WO03068921 A3 WO 03068921A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
acids encoding
encoding same
therapeutic polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/004188
Other languages
French (fr)
Other versions
WO2003068921A2 (en
Inventor
Luca Rastelli
Haihong Zhong
Ferenc L Boldog
Esha A Gangolli
Xiaojia Guo
Uriel M Malyankar
Meera Patturajan
Carol E A Pena
Richard A Shimkets
Kimberley A Spytek
Corine A M Vernet
Daniel K Rieger
Shlomit R Edinger
Catherine E Burgess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to AU2003219743A priority Critical patent/AU2003219743A1/en
Publication of WO2003068921A2 publication Critical patent/WO2003068921A2/en
Publication of WO2003068921A3 publication Critical patent/WO2003068921A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel polypeptides, and the nucleic acids encoding them, having properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.
PCT/US2003/004188 2002-02-12 2003-02-12 Therapeutic polypeptides, nucleic acids encoding same, and methods of use Ceased WO2003068921A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003219743A AU2003219743A1 (en) 2002-02-12 2003-02-12 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35637502P 2002-02-12 2002-02-12
US60/356,375 2002-02-12
US38708202P 2002-06-07 2002-06-07
US60/387,082 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003068921A2 WO2003068921A2 (en) 2003-08-21
WO2003068921A3 true WO2003068921A3 (en) 2004-04-08

Family

ID=27737531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004188 Ceased WO2003068921A2 (en) 2002-02-12 2003-02-12 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (2)

Country Link
AU (1) AU2003219743A1 (en)
WO (1) WO2003068921A2 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUGUET E.L. ET AL.: "Differential expression of human Wnt genes 2, 3, 4 and 7B in human breast cell lines and normal and disease states of human breast tissue", CANCER RES., vol. 54, no. 10, 15 May 1994 (1994-05-15), pages 2615 - 2621, XP002121611 *

Also Published As

Publication number Publication date
AU2003219743A8 (en) 2003-09-04
WO2003068921A2 (en) 2003-08-21
AU2003219743A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
WO2003031572A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
WO2004013310A3 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
ATE209684T1 (en) DNA SEQUENCES FOR MATRIX METAL PROTEASES, THEIR PREPARATION AND USE
WO2003076578A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003029429A3 (en) Traversal of nucleic acid molecules through a fluid space and expression in repair cells
WO2002040672A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2004050907A3 (en) Method for determing predisposition to manifestation of immune system related diseases
WO2004018633A3 (en) Abca13 nucleic acids and proteins, and uses thereof
HRP20020093A2 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
WO2003068921A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
EP2075346A3 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2005014804A3 (en) Ubiquitin-specific protease
WO2001049879A3 (en) Methods for comparing gene expression levels or patterns in normal or tumor cells
EP1494031A3 (en) Novel human genes and gene expression products
CY1110911T1 (en) Human TSC403 gene
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2006034007A3 (en) Methods of treating metabolic disorders by modulation of salt-inducible serine/threonine kinase 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP